<DOC>
	<DOCNO>NCT00028717</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody rituximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining monoclonal antibody therapy chemotherapy may kill tumor cell . It yet know combination chemotherapy plus filgrastim effective without rituximab treat non-Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial determine effectiveness combination chemotherapy plus filgrastim without rituximab treat old patient non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Filgrastim With Without Rituximab Treating Older Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) , filgrastim ( G-CSF ) without rituximab event-free survival elderly patient intermediate high-risk non-Hodgkin 's lymphoma . - Compare complete remission rate , overall survival , disease-free survival patient treat regimen . - Compare toxicity regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , WHO classification , International Prognostic Index score . Patients randomize 1 2 treatment arm . - Arm I : Patients receive cyclophosphamide IV , doxorubicin IV , vincristine IV day 1 ; oral prednisone day 1-5 ; filgrastim ( G-CSF ) subcutaneously day 1-14 . Treatment repeat every 2 week 8 course absence disease progression unacceptable toxicity . - Arm II : Patients receive cyclophosphamide , doxorubicin , vincristine , prednisone , G-CSF arm I . Patients also receive rituximab IV day 3 course 1-2 day 1 course 3-6 total 6 dos . Patients follow every 3 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 400 patient ( 200 per treatment arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonHodgkin 's lymphoma ( NHL ) Low highintermediate highrisk lymphoma follow subtypes : Mantle cell lymphoma Follicular lymphoma ( grade III ) Diffuse large Bcell lymphoma CD20positive No suspect document CNS involvement NHL NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 65 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 1.75 mg/dL* Transaminases le 2.5 time normal* NOTE : * Unless due NHL Renal : Creatinine le 1.7 mg/dL ( unless due NHL ) Cardiovascular : No severe cardiac dysfunction No New York Heart Association class IIIV heart disease LVEF least 45 % Pulmonary : No uncontrolled asthma require steroid treatment Other : HIV negative No intolerance exogenous protein administration No active , uncontrolled infection No uncontrolled allergy require steroid treatment No malignancy within past 5 year except basal cell skin cancer stage 0 cervical cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy NHL Chemotherapy : No prior chemotherapy NHL Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy NHL except local radiotherapy potential organ dysfunction localize lymphoma mass infiltration Concurrent local radiotherapy potential actual organ dysfunction localize lymphoma mass infiltration allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>